Czechia vs Netherlands: The number of people with susceptibility test result for rifampicin
Czechia
239
in 2021
Netherlands
270
in 2021
Czechia rank
90th
Netherlands rank
88th
The number of people with susceptibility test result for rifampicin over time
- Czechia
- Netherlands
How they compare
Netherlands currently reports 270 against 239 in Czechia, a difference of 31.
That makes Netherlands's figure about 1.1 times Czechia's.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Netherlands ahead.
Czechia ranks 90th and Netherlands ranks 88th of 155 countries.
Netherlands has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Czechia | Netherlands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 294 | 322.33 | 28.33 | Netherlands |
| 2020s | 231 | 257 | 26 | Netherlands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Czechia or Netherlands?
- Netherlands, at 270 against 239 in Czechia as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Czechia and Netherlands?
- 31, with Netherlands ahead.
- How many years of comparable data are there for Czechia and Netherlands?
- 5 years are reported by both, from 2017 to 2021.
- How do Czechia and Netherlands rank globally for the number of people with susceptibility test result for rifampicin?
- Czechia ranks 90th and Netherlands ranks 88th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.